Owkin and CRO Aviano Sign Master Partnership Agreement to Foster Collaborative Oncology Research

PARIS & PORDENONE, Italy — Owkin, the agentic AI company pioneering the first autonomous AI scientist to revolutionize drug discovery and development, and the Centro di Riferimento Oncologico di Aviano (CRO), a leading Italian National Cancer Institute (IRCCS) dedicated to research and care, today announced the signature of a Master Partnership Agreement aimed at facilitating connections and collaborative research projects in the field of oncology.

CRO Aviano is currently undertaking a significant strategic investment in both economic and personnel resources to structure, digitalize and unlock the potential of its clinical data assets. This ongoing process aims to establish a fully operational technological ecosystem over the coming years to support internal researchers, drive new oncological discoveries and ultimately advance cancer treatment.

Within this framework, Owkin will serve as a scientific and technological partner. Owkin will facilitate collaboration with third-party partners and drive the activation of new research projects. The collaboration will also enable the exploration of advanced privacy-preserving technologies and federated analysis models, ensuring that any future synergy complies fully with GDPR regulations and the highest standards of healthcare data security.

‍

Thomas Clozel, MD, Co-founder and CEO, Owkin:

The future of oncology research depends on access to real, high-quality clinical data at scale. Our partnership with CRO Aviano strengthens the data foundation that Owkin’s AI Scientist K Pro draws from to help researchers understand complex biology and move faster toward new therapies.

Gustavo Baldassarre, Scientific Director, Centro di Riferimento Oncologico di Aviano:

The strategic goal of CRO Aviano is to streamline and organize our information assets, transforming them into a robust resource for clinical research. This master agreement with Owkin fits into a multi-year journey of digitalization and optimization of our clinical software applications. This collaboration allows us to engage with international networks as active scientific partners while maintaining total control over our data and guaranteeing the highest standards of patient privacy.